Corcept Therapeutics Inc. (CORT) saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.

The biopharmaceutical company, which specializes in the discovery and development of drugs for endocrinologic, oncologic, metabolic, and neurologic disorders, has been on a remarkable run this year. As of November 5th, CORT's stock has gained a staggering 60.5% year-to-date.

One of the key drivers behind this surge is the massive demand for Corcept's flagship drug, Korlym, which is approved for treating Cushing's syndrome. The company is also expecting to file a new drug application for its lead candidate, relacorilant, to treat Cushing's syndrome in the fourth quarter of 2024.